Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356135 · ClinicalTrials.gov registry record · Phase 2
Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 139
- Enrollment target
NCT00356135 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 139 participants.
The verdict
NCT00356135, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 139 participants
- Enrollment target
Study Summary
This study will compare the effect of a prasugrel 10-mg maintenance dose with a clopidogrel 75-mg maintenance dose on platelet activity, approximately 1 week after the first dose of study drug, in subjects who have been taking clopidogrel 75 mg daily following a percutaneous coronary intervention (PCI) with placement of a stent, performed to treat acute coronary syndrome (ACS).
Interventions
- DRUG clopidogrel
- DRUG prasugrel 10 mg
- DRUG prasugrel placebo
- DRUG prasugrel 60 mg
- DRUG clopidogrel placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00356135
The ClinicalTrials.gov registry entry for NCT00356135 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which clopidogrel is the first listed.
NCT00356135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00356135 about?
NCT00356135 is a clinical study titled "Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event". This study will compare the effect of a prasugrel 10-mg maintenance dose with a clopidogrel 75-mg maintenance dose on platelet activity, approximately 1 week after the first dose of study drug, in subjects who have been taking clopidogrel 75 mg daily following a percutaneous coronary intervention (P...
What is the current status of trial NCT00356135?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 139 participants. The study started on 2006-07. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00356135?
The interventions under investigation include: clopidogrel (DRUG), prasugrel 10 mg (DRUG), prasugrel placebo (DRUG), prasugrel 60 mg (DRUG), clopidogrel placebo (DRUG).
Who is sponsoring clinical trial NCT00356135?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.